Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Ready to Unveil First Array-Based Genotyping Tool Early '99

Premium

SANTA CLARA, Calif.--In its latest quarterly earnings report, Affymetrix noted significant progress in each of its three business areas: gene expression profiling, polymorphism analysis, and disease management. The company also unveiled a new bioinformatics product, the GeneChip Expression Data Mining Tool, during the quarter ended September 30.

In addition, Affymetrix said it continued beta-testing its first genotyping product, a GeneChip probe array containing over 2,000 common polymorphisms that was developed in collaboration with the Whitehead Institute.

The product, scheduled for launch in the first quarter of 1999, will be the first commercially available array-based genotyping tool, Affymetrix claimed.

The company reported that sales for the quarter increased 521 percent, to $6.5 million, and revenue grew 200 percent, to $15 million, compared to the same period last year.

Filed under

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.